凯普生物2024年净利润暴跌566% 两大核心业务收入下滑超20%

Core Insights - The company reported a significant decline in revenue and increased net losses for the year 2024, primarily due to the impact of centralized procurement policies on its HPV-DNA testing products and medical testing services [2][5] Financial Performance - The company achieved a revenue of 815 million yuan in 2024, representing a year-on-year decrease of 26.16% [2] - The net loss attributable to shareholders was 655 million yuan, a substantial increase of 566.20% compared to the previous year [2] - The non-recurring net loss was 660 million yuan, reflecting a decrease of 682.84% year-on-year [2] - Basic earnings per share were reported at -1.02 yuan [2] Business Segments - The molecular diagnostics segment generated revenue of 568 million yuan, down 20% year-on-year, accounting for 69.7% of total revenue [5] - The HPV testing sales volume was approximately 9 million units, with cumulative usage exceeding 75 million [5] - The medical testing services segment reported revenue of 241 million yuan, a decline of 38.48%, contributing 29.57% to total revenue [5] Financial Structure - Total assets decreased by 19.26% to 4.622 billion yuan, with accounts receivable at 1.094 billion yuan, down 42% year-on-year [5] - Total liabilities stood at 576 million yuan, resulting in a debt-to-asset ratio of 14.47% [5] - The net cash flow from operating activities was 79 million yuan, a decrease of 75.35% year-on-year [5] - The weighted average return on equity was reported at -14.62% [5] Research and Development - The company invested 102 million yuan in R&D, representing 12.57% of its revenue [5] - It obtained 6 new Class III medical device registrations and 30 domestic and international patents, bringing the total to 192 patents [5] - New products launched included cervical cancer methylation detection reagents and fully automated nucleic acid detection systems, aimed at enhancing tumor early screening and detection automation [5]